Sep 28th 2012 - Edison Investment Research today published a report on 4SC entitled "50% Boost In HCC Survival". In summary, the report says:
New data from 4SC’s SHELTER study in advanced, second-line hepatocellular carcinoma (HCC) show an 8.0 month median overall survival for resminostat when given with Nexavar (sorafenib, Bayer), some three months (c 50%) longer than would be expected. The data support a move into Phase III trials in the second- and potentially first-line HCC indications, pending the formation of a global (ex-Japan) partnership.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
